If you have been reading about alpha-MSH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-15. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
== Other uses == DL-Methionine is sometimes given as a supplement to dogs; It helps reduce the chances of kidney stones in dogs. Methionine is also known to increase the urinary excretion of quinidine by acidifying the urine. Aminoglycoside antibiotics used to treat urinary tract infections work best in alkaline conditions, and urinary acidification from using methionine can reduce its effectiveness. If a dog is on a diet that acidifies the urine, methionine should not be used. Methionine is allowed as a supplement to organic poultry feed under the US certified organic program. Methionine can be used as a nontoxic pesticide option against giant swallowtail caterpillars, which are a serious pest to orange crops.
== See also == Psilocybin decriminalization in the United States Timeline of psychedelic legalization and decriminalization Legal status of psychedelic drugs in Canada Legal status of psychedelic drugs in the United Kingdom Legal status of psilocybin mushrooms Legal status of ayahuasca by country Legal status of psychoactive cacti by country Legal status of ibogaine by country Online illicit drug vendor
is unstable. Starting from almost everywhere in the concentration space, the system evolves to a homochiral state. It is generally understood that autocatalysis alone does not yield homochirality, and the presence of the mutually antagonistic relationship between the two enantiomers is necessary for the instability of the racemic mixture. Homochirality could be achieved from autocatalysis in the absence of the mutually antagonistic relationship, but the underlying mechanism for symmetry-breaking is different.
Sources: en.wikipedia.org
== AMPA Receptors in Disease Beyond Epilepsy == AMPA receptors are essential to excitatory neurotransmission in the CNS. Beyond their established role in epilepsy, recent research indicates that AMPARs are implicated in various neurological and psychiatric disorders, including excitotoxicity in stroke and neurodegeneration, as well as conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Huntington's disease, schizophrenia, and autism spectrum disorders (ASD).
The International Rice Research Institute and the International Maize and Wheat Improvement Center are part of a consortium of agricultural research organizations known as CGIAR. Costing around $600 million, over 50 years, the revolution brought new farming technology, increased productivity, expanded crop yields and mass fertilization to many countries throughout the world. Later it funded over $100 million of plant biotechnology research and trained over four hundred scientists from Asia, Africa and Latin America. It also invested in the production of transgenic crops, including rice and maize. In 1999, the then president Gordon Conway addressed the Monsanto Company board of directors, warning of the possible social and environmental dangers of this biotechnology, and requesting them to disavow the use of so-called terminator genes; the company later complied. In the 1990s, the foundation shifted its agriculture work and emphasis to Africa; in 2006, it joined with the Bill & Melinda Gates Foundation in a $150 million effort to fight hunger in the continent through improved agricultural productivity. In an interview marking the 100 year anniversary of the Rockefeller Foundation, Judith Rodin explained to This Is Africa that Rockefeller has been involved in Africa since their beginning in three main areas – health, agriculture and education, though agriculture has been and continues to be their largest investment in Africa.
An mRNA vaccine (or RNA vaccine) is a novel type of vaccine which is composed of the nucleic acid RNA, packaged within a vector such as lipid nanoparticles. Among the COVID-19 vaccines are a number of RNA vaccines to combat the COVID-19 pandemic and some have been approved or have received emergency use authorization in some countries. For example, the Pfizer-BioNTech vaccine and Moderna mRNA vaccine are approved for use in adults and children in the US.
Sources: en.wikipedia.org
== Research == The best known CCK receptor antagonist is the non-selective antagonist proglumide, which blocks both CCKA and CCKB receptors, and was originally developed for the treatment of stomach ulcers. This action derived from its blockade of CCKA receptor in the gut and consequent reduction in secretion of gastric acid, however a side effect of proglumide was found, namely that it increases the analgesic effects of opioid painkillers, and decreases the development of tolerance. This was subsequently found to result from its blockade of CCKB receptors in the brain. Another CCK receptor antagonist is benzotript, which is likewise non-selective. Newer drugs have since been developed which are selective for one or other of the CCK receptors. Selective CCKA receptor antagonists such as lorglumide and devazepide have been developed both for their anti-ulcer effects and as potential drugs to limit the development of gastrointestinal cancers such as colon cancer. A centrally selective antagonist—Ranquilon—has recently undergone clinical approval for the treatment of anxiety in Russia. The main focus of CCK receptor antagonist research has focused on the development of selective CCKB receptor antagonists as novel medications which have been primarily investigated for the treatment of anxiety and panic attacks, as well as for other roles such as analgesic effects.
=== Section Cyclopia === Cyclopia alpina A.L. Schutte Cyclopia falcata (Harv.) Kies (= Cyclopia subternata Vogel) Cyclopia galioides (Bergius) DC. Cyclopia genistoides (L.) Vent. Cyclopia intermedia E. Mey.
Kropotkin, Peter Alexeivitch (1911). "Cossacks" . Encyclopædia Britannica. Vol. 7 (11th ed.). p. 218. "Cossacks during the Napoleonic Wars". "Zaporizhian Cossacks". "Encyclopedia of Ukraine". "History of Ukrainian Cossacks". "Encyclopedia of Ukraine". Soviet Cossacks (photography). Archived from the original on 2011-11-13. Retrieved 2010-07-27. – an issue of the propaganda journal USSR in Construction which presents numerous images of Cossack life in Soviet Russia. "Cossack Nation Live journal". {{cite web}}: Check |url= value (help) "Cossack Nation – The Social Network of Ethnic Cossacks". "The Congress of Cossacks in America". "Pirate, Rebel, Freedom Fighter, Champion of the Poor". Archived from the original on 2007-08-05. Retrieved 2015-04-03. "History of the Cossacks 15–21st centuries". Open Public Library. Documents, maps, illustrations Peeling, Siobhan. "Cossacks". "International Encyclopedia of the First World War". 1914–1918 online. Archived from the original on 2019-12-30. Retrieved 2019-06-18.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.